3 weeks ago
6
Article content
VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” oregon the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical institution advancing crab therapies done AI-enabled cause discovery, contiguous announced that caller information volition beryllium presented successful 2 posters astatine the Society for Neuro-Oncology (SNO) Annual Meeting, taking spot November 19–23, 2025, successful Honolulu, Hawaii.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe present to work the latest quality successful your metropolis and crossed Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily contented from Financial Times, the world's starring planetary concern publication.
- Unlimited online entree to work articles from Financial Post, National Post and 15 quality sites crossed Canada with 1 account.
- National Post ePaper, an physics replica of the people variation to presumption connected immoderate device, stock and remark on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe present to work the latest quality successful your metropolis and crossed Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily contented from Financial Times, the world's starring planetary concern publication.
- Unlimited online entree to work articles from Financial Post, National Post and 15 quality sites crossed Canada with 1 account.
- National Post ePaper, an physics replica of the people variation to presumption connected immoderate device, stock and remark on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an relationship oregon motion successful to proceed with your speechmaking experience.
- Access articles from crossed Canada with 1 account.
- Share your thoughts and articulation the speech successful the comments.
- Enjoy further articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an relationship oregon motion successful to proceed with your speechmaking experience.
- Access articles from crossed Canada with 1 account
- Share your thoughts and articulation the speech successful the comments
- Enjoy further articles per month
- Get email updates from your favourite authors
Sign In oregon Create an Account
or
Article content
The presentations volition item Rakovina’s AI-driven programs to observe and make next-generation DNA-damage effect (DDR) inhibitors engineered for cardinal tense strategy (CNS) penetration, supporting the improvement of imaginable caller attraction options for superior and metastatic encephalon cancers.
Article content
Article content
Article content
Presentation Details:
Article content
By signing up you consent to person the supra newsletter from Postmedia Network Inc.
Article content
Title: Discovery and improvement of a caller CNS-penetrating ATR inhibitor
Session: Poster Session – DNA Repair (DNAR-05)
Date/Time: November 21, 2025 | 11:30 a.m.–12:45 p.m. (HST)
Article content
Title: Discovery and improvement of caller CNS-penetrating PARP1-selective inhibitors
Session: Poster Session – DNA Repair (DNAR-06)
Date/Time: November 21, 2025 | 11:30 a.m.–12:45 p.m. (HST)
Article content
The archetypal poster presents results from Rakovina Therapeutics’ kt-5000AI ATR inhibitor program, developed successful collaboration with Variational AI. The programme leverages the ENKI™ generative AI level to plan and optimize CNS-penetrant ATR inhibitors with favorable pharmacologic properties for the imaginable attraction of encephalon cancers. The information item the find of potent, selective ATR inhibitors that show enactment against treatment-resistant tumor phenotypes.
Article content
The 2nd poster presents advancement from the Company’s kt-2000AI PARP inhibitor program, developed utilizing the Deep Docking™ AI-accelerated cause find platform. The programme applies ultra-large-scale virtual screening to measure billions of compounds successful silico, rapidly identifying and optimizing PARP1-selective, CNS-penetrant inhibitors with desirable pharmacologic properties. The information exemplify however this attack enables heavy exploration of chemic abstraction and businesslike find of next-generation candidates designed to code the limitations of first-generation PARP inhibitors.
Article content
Article content
“The Society for Neuro-Oncology Annual Meeting is simply a premier planetary forum for advances successful encephalon crab research, and we’re arrogant to stock our latest information astatine this year’s conference,” said Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “Our information reflects Rakovina’s ongoing efforts to make first-in-class DNA-damage effect inhibitors designed to scope the brain. By combining AI-accelerated medicinal chemistry with the world-class infrastructure astatine the University of British Columbia’s Vancouver Prostate Centre, we are advancing next-generation therapies targeting ATR and PARP1 pathways aimed astatine improving outcomes for patients with assertive and treatment-resistant encephalon cancers.”
Article content
About the Society for Neuro-Oncology (SNO)
The Society for Neuro-Oncology (SNO) Annual Meeting, held successful concern with the World Federation of Neuro-Oncology Societies (WFNOS), is the premier planetary league dedicated to advancing the subject and attraction of encephalon cancers. The 2025 gathering successful Honolulu, Hawaii, volition unite starring researchers, clinicians, and manufacture innovators from astir the satellite to showcase groundbreaking discoveries and emerging therapeutic strategies successful neuro-oncology. Recognized arsenic 1 of the astir influential forums successful the field, SNO provides an unparalleled accidental for visibility and collaboration crossed the planetary encephalon crab community. For much information, delight visit: https://www.soc-neuro-onc.org/SNO2025/SNO2025/Home.aspx
.jpg)
English (US)